Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis
Vivek Patel(Vanderbilt University Medical Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Adetola A. Kassim(Vanderbilt University), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Tae Kon Kim(Vanderbilt University), David Morgan(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Bipin N. Savani(Vanderbilt University Medical Center), Katherine E. Baker(Vanderbilt University Medical Center), Danielle Fishman(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Trent Morris(Vanderbilt University Medical Center), Spencer Lessans(Vanderbilt University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782